These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 9823536)

  • 1. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
    Jones RN; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
    Jones RN; Barrett MS; Deguchi T
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
    Jones RN; Johnson DM; Erwin ME; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):91-8. PubMed ID: 10354857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden.
    Liljequist BO; Hoffman BM; Hedlund J
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):671-5. PubMed ID: 8894578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
    Zhanel GG; Palatnick L; Nichol KA; Bellyou T; Low DE; Hoban DJ
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1867-74. PubMed ID: 12760860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.
    Urbásková P; Trupl J; Hupková H; Appelbaum PC; Jacobs MR
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):686-8. PubMed ID: 8894582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
    Nicodemo AC; Mendes CM; Oplustil CP; Sinto S
    Braz J Infect Dis; 2001 Apr; 5(2):50-2. PubMed ID: 11493408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
    Hoban DJ; Bouchillon SK; Karlowsky JA; Johnson JL; Butler DL; Miller LA; Poupard JA
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).
    Odland BA; Jones RN; Verhoef J; Fluit A; Beach ML
    Diagn Microbiol Infect Dis; 1999 Aug; 34(4):315-20. PubMed ID: 10459483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.
    Thomson KS; Chartrand SA; Sanders CC; Block SL
    Antimicrob Agents Chemother; 1997 Feb; 41(2):478-80. PubMed ID: 9021213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
    Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
    Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
    Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.